Want to see TSE:MVMD full AI Analyst Report?
MVMD Stock Chart & Stats
C$0.08
<C$0.01(6.67%)
At close: 4:00 PM EDT
C$0.08
<C$0.01(6.67%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.11
Previous CloseN/A
Volume86.00K
Average Volume (3M)205.59K
Market Cap
C$34.28M
Enterprise ValueC$5.06
Total Cash (Recent Filing)C$334.00K
Total Debt (Recent Filing)C$403.00K
Price to Earnings (P/E)―
Beta-1.02
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding457,002,000
10 Day Avg. Volume152,980
30 Day Avg. Volume205,595
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-199.92
Price to Sales (P/S)433.67
P/FCF Ratio-13.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Delivery/solubilization Technology PlatformA stated focus on delivery and solubilization platforms signals a structural, differentiated capability in formulation and absorption. Such platform technology can drive recurring product licensing, higher-margin formulations, and multi-product application across nutraceuticals and life sciences over the medium term.
Revenue Rebound And Loss Narrowing (2026)A sharp revenue rebound and materially narrowed losses in 2026 indicate early operational improvement and potential stabilization. If the company sustains revenue growth trends and continues cost discipline, this provides a pathway to reduce burn and extend runway versus prior years.
Modest Nominal Debt BurdenLow absolute debt limits fixed financial obligations and reduces near-term insolvency risk relative to higher-leverage peers. With modest nominal liabilities, management has more flexibility to prioritize R&D, restructuring, or strategic partnerships without heavy interest servicing constraints.
Bears Say
Persistent Negative Operating And Free Cash FlowSustained operating and free cash outflows show the business cannot self-fund operations, requiring external capital to continue. Over months this erodes runway, forces dilution or debt, and constrains investment in commercial scaling or R&D critical for long-term competitiveness.
Negative Shareholders' Equity And Shrunken Asset BaseNegative equity signals accumulated losses that have eroded the capital base, weakening solvency metrics and limiting ability to absorb further shocks. The dramatic shrinkage in assets reduces operational scale and collateral availability, hampering strategic options and creditor confidence.
Very Small, Volatile Revenue And Weak MarginsTiny and unstable revenue combined with deeply negative margins indicate the company lacks a resilient, scalable commercial model today. Structural unprofitability relative to revenue means continued reliance on funding; without durable margin improvement, growth will not translate into sustainable profitability.
Mountain Valley MD News
MVMD FAQ
What was Mountain Valley MD’s price range in the past 12 months?
Mountain Valley MD lowest stock price was C$0.01 and its highest was C$0.10 in the past 12 months.
What is Mountain Valley MD’s market cap?
Mountain Valley MD’s market cap is C$34.28M.
When is Mountain Valley MD’s upcoming earnings report date?
Mountain Valley MD’s upcoming earnings report date is Sep 02, 2026 which is in 31 days.
How were Mountain Valley MD’s earnings last quarter?
Currently, no data Available
Is Mountain Valley MD overvalued?
According to Wall Street analysts Mountain Valley MD’s price is currently Overvalued.
Does Mountain Valley MD pay dividends?
Mountain Valley MD does not currently pay dividends.
What is Mountain Valley MD’s EPS estimate?
Mountain Valley MD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mountain Valley MD have?
Mountain Valley MD has 457,002,000 shares outstanding.
What happened to Mountain Valley MD’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mountain Valley MD?
Currently, no hedge funds are holding shares in TSE:MVMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mountain Valley MD
Mountain Valley MD Holdings Inc., operating through its subsidiary Mountain Valley MD Inc., functions as a health and wellness enterprise. The company focuses on deploying and licensing its proprietary innovations to external entities within the pharmaceutical, vaccine, and nutritional supplement sectors. Its portfolio encompasses Quicksome, an advanced technology for oral drug formulation and delivery; Quicksol, designed for enhancing solubility; and a dose-sparing adjuvant. Additionally, the firm is actively developing IM032, a compound currently being evaluated in male beagle dogs to assess intramuscular versus subcutaneous administration methods. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.